On March 1, Molnupiravir, a specific COVID-19 drug developed and produced by TLPH, was approved for marketing by the Food and Drug Department (FDD) of the Ministry of Health of Laos, with emergency use authorization granted by FDD! This means that this oral drug, which is attracting worldwide attention, will help Laos and other countries along the Belt and Road effectively cope with and control the COVID-19 epidemic.

Molnupiravir is the world's first COVID-19 oral drug launched by Merck, known as the "king of vaccines", in November 2021. Clinical data confirm that taking four capsules twice daily for 5 days reduces the risk of hospitalization or death by 50% in patients with mild or moderate disease. 

As the first oral preparation, Molnupiravir is important because it allows COVID-19 patients to avoid hospital treatment and instead take the drug at home for antiviral treatment. This has greatly improved access and efficiency.

TLPH actively responded to the call of the Lao government, strictly according to the standards of original research drugs, through a series of technical breakthroughs, successfully completed drug research and development and production, and was highly recognized and appreciated by FDD. Molnupiravir, sold under the brand name Molavir, comes in a 200mg bottle of 40 pills, the same as the original drug.